Altesa BioSciences Appoints Brett Haumann, MBBCh, MBA, to its Board of Directors and Gwen Skloot, MD, ATSF, as Senior Vice President for Clinical Development

▤ Summary

Altesa BioSciences named Brett Haumann to its Board of Directors and Gwen Skloot as Senior Vice President for Clinical Development. Both executives bring deep respiratory and clinical development experience from major pharma and biotech roles. The company said the appointments support its Phase 2b CARDINAL trial of vapendavir for COPD patients affected by rhinovirus. The move strengthens Altesa’s leadership as it advances a late-stage program aimed at reducing COPD exacerbations.

▦ Linked Companies